Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down on Disappointing Earnings

Summit Therapeutics PLC (NASDAQ:SMMT) gapped down prior to trading on Friday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $14.98, but opened at $13.72. Summit Therapeutics shares last traded at $13.5480, with a volume of 1,571,258 shares changing hands.

The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01).

More Summit Therapeutics News

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: Summit reported updated Phase III survival data for its HARMONi lung cancer study and said its lead drug ivonescimab continues to advance, including new development collaborations that broaden its pipeline optionality. Article Title
• Positive Sentiment: Unusually heavy options activity, with call volume far above normal, suggests traders are positioning for a possible rebound or additional catalyst-driven upside.
• Neutral Sentiment: The company’s Q2 earnings call and presentation focused on clinical and operational progress, keeping attention on future data readouts rather than near-term revenue generation. Article Title
• Neutral Sentiment: HC Wainwright reaffirmed a neutral rating, reinforcing that analysts remain cautious while waiting for clearer evidence that ivonescimab can deliver commercially meaningful results. Article Title
• Negative Sentiment: Summit posted a wider-than-expected Q2 loss with no revenue, highlighting continued cash burn and reliance on future clinical success to justify its valuation. Article Title
• Negative Sentiment: An article noted that analyst expectations were being tempered after the initial lung cancer survival data, which may be pressuring sentiment and contributing to the stock’s recent weakness. Article Title

Analyst Upgrades and Downgrades

A number of analysts have commented on SMMT shares. Wall Street Zen downgraded Summit Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Stifel Nicolaus dropped their price target on Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating for the company in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Summit Therapeutics in a research note on Friday. Citigroup initiated coverage on shares of Summit Therapeutics in a research report on Wednesday, April 8th. They issued a “buy” rating on the stock. Finally, Sanford C. Bernstein initiated coverage on Summit Therapeutics in a research report on Thursday, May 21st. They set an “underperform” rating and a $7.70 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $26.15.

Insider Activity at Summit Therapeutics

In other news, CEO Robert W. Duggan bought 3,810,000 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were purchased at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the completion of the transaction, the chief executive officer owned 573,883,879 shares in the company, valued at $7,529,356,492.48. The trade was a 0.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Manmeet Singh Soni bought 50,000 shares of the stock in a transaction on Thursday, June 4th. The stock was purchased at an average cost of $14.45 per share, with a total value of $722,500.00. Following the completion of the purchase, the chief financial officer directly owned 3,123,603 shares in the company, valued at $45,136,063.35. This trade represents a 1.63% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have bought 7,870,000 shares of company stock valued at $103,616,900. Company insiders own 83.50% of the company’s stock.

Institutional Investors Weigh In On Summit Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in SMMT. Baker BROS. Advisors LP lifted its position in Summit Therapeutics by 7.9% during the fourth quarter. Baker BROS. Advisors LP now owns 36,391,063 shares of the company’s stock worth $636,480,000 after buying an additional 2,668,089 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Summit Therapeutics in the 4th quarter valued at about $1,043,000. TD Asset Management Inc increased its stake in shares of Summit Therapeutics by 124.2% during the 4th quarter. TD Asset Management Inc now owns 1,205,272 shares of the company’s stock valued at $21,080,000 after acquiring an additional 667,742 shares during the last quarter. Polymer Capital Management HK LTD increased its stake in shares of Summit Therapeutics by 73.9% during the 4th quarter. Polymer Capital Management HK LTD now owns 1,421,155 shares of the company’s stock valued at $24,856,000 after acquiring an additional 603,879 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Summit Therapeutics during the 4th quarter worth about $24,030,000. Hedge funds and other institutional investors own 4.61% of the company’s stock.

Summit Therapeutics Stock Performance

The company’s fifty day moving average price is $15.03 and its two-hundred day moving average price is $16.68. The firm has a market capitalization of $10.60 billion, a PE ratio of -12.20 and a beta of -1.26.

About Summit Therapeutics

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.